Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Kardiologie
Erschienen in: Die Kardiologie 4/2020

13.05.2020 | EKG | Konsensuspapiere

Onkologische Kardiologie

Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie

verfasst von: Univ.-Prof. Dr. med. Tienush Rassaf, Matthias Totzeck, Johannes Backs, Carsten Bokemeyer, Michael Hallek, Denise Hilfiker-Kleiner, Andreas Hochhaus, Diana Lüftner, Oliver J. Müller, Ulrich Neudorf, Roman Pfister, Stephan von Haehling, Lorenz H. Lehmann, Johann Bauersachs, die Kommission für Klinische Kardiovaskuläre Medizin der DGK

Erschienen in: Die Kardiologie | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Akut- und Langzeitnebenwirkungen der modernen, multimodalen Tumortherapie beeinträchtigen signifikant Lebensqualität und Überleben von Patienten mit Malignomen. Zu den wesentlichen Komponenten dieser Therapie zählen Strahlen-, die klassische (konventionelle) Chemo‑, Immun- sowie die sog. zielgerichteten Therapien. Zu etablierten Tumortherapiestrategien kommen bis zu 30 Neuzulassungen pro Jahr mit nur unvollständig charakterisierten Nebenwirkungsprofilen. Dieses Konsensuspapier adressiert die Risikofaktoren für eine mögliche adverse Reaktion unter Tumortherapie und führt im Weiteren spezifische Nebenwirkungsprofile für die verschiedenen Therapiegruppen auf. Schwerpunktmäßig wird auf neuartige Therapeutika eingegangen und Empfehlungen zur Behandlung spezifischer Patientengruppen aufgeführt.
Literatur
1.
Abdel-Rahman O (2019) 5‑fluorouracil-related cardiotoxicity; findings from five randomized studies of 5‑fluorouracil-based regimens in metastatic colorectal cancer. Clin Colorectal Cancer 18:58–63PubMed
2.
Agewall S, Giannitsis E, Jernberg T et al (2011) Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 32:404–411PubMed
3.
Anquetil C, Salem JE, Lebrun-Vignes B et al (2018) Immune checkpoint inhibitor-associated myositis. Circulation 138:743–745PubMed
4.
Armenian SH, Hudson MM, Mulder RL et al (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123–e136PubMedPubMedCentral
5.
Armenian SH, Lacchetti C, Barac A et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35:893–911PubMed
6.
Armenian SH, Sun CL, Francisco L et al (2008) Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 26:5537–5543PubMedPubMedCentral
7.
Armenian SH, Xu L, Ky B et al (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122–1130PubMedPubMedCentral
8.
Armstrong GT, Joshi VM, Ness KK et al (2015) Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the st. Jude lifetime cohort study. J Am Coll Cardiol 65:2511–2522PubMedPubMedCentral
9.
Atkins KM, Rawal B, Chaunzwa TL et al (2019) Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol 73:2976PubMed
10.
Barac A, Blaes A, Lynce F (2019) Lessons from primary cardiac prevention trials during trastuzumab therapy: end of one size fits all. J Am Coll Cardiol 73:2869–2871PubMed
11.
Bhatia S (2011) Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev 20:2048–2067PubMedPubMedCentral
12.
Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293–1305PubMedPubMedCentral
13.
Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714–1768PubMed
14.
Braumann S, Peitsch WK, Pfister R et al (2019) Angina pectoris in a 47-year-old athletic man with psoriasis vulgaris. Internist 60:86–89PubMed
15.
Burridge PW, Li YF, Matsa E et al (2016) Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 22:547–556PubMedPubMedCentral
16.
Caforio AL, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636–2648 (2648a–2648d)PubMed
17.
Calvillo-Arguelles O, Abdel-Qadir H, Michalowska M et al (2019) Cardioprotective effect of Statins in patients with HER2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol 35:153–159PubMed
18.
Caocci G, Mulas O, Bonifacio M et al (2019) Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol 288:124–127PubMed
19.
Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–1988PubMed
20.
Centanni M, Moes D, Troconiz IF et al (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58:835–857PubMedPubMedCentral
21.
Chang HM, Okwuosa TM, Scarabelli T et al (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol 70:2552–2565PubMedPubMedCentral
22.
Chari A, Stewart AK, Russell SD et al (2018) Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv 2:1633–1644PubMedPubMedCentral
23.
24.
Chow EJ, Baker KS, Lee SJ et al (2014) Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 32:191–198PubMed
25.
Chow EJ, Chen Y, Hudson MM et al (2018) Prediction of ischemic heart disease and stroke in survivors of childhood cancer. J Clin Oncol 36:44–52PubMed
26.
Cornell RF, Ky B, Weiss BM et al (2019) Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 37:1946–1955PubMed
27.
Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783–1796PubMed
28.
29.
Cuomo JR, Sharma GK, Conger PD et al (2016) Novel concepts in radiation-induced cardiovascular disease. World J Cardiol 8:504–519PubMedPubMedCentral
30.
31.
Danhof S, Schreder M, Rasche L et al (2016) ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma—analysis of cardiac toxicity and predisposing factors. Eur J Haematol 97:25–32PubMed
32.
Darby SC, Ewertz M, Mcgale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998PubMed
33.
De Azambuja E, Ameye L, Diaz M et al (2015) Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer 51:2517–2524PubMed
34.
Desai MY, Windecker S, Lancellotti P et al (2019) Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC scientific expert panel. J Am Coll Cardiol 74:905–927PubMed
35.
Dimopoulos MA, Chen C, Spencer A et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147–2152PubMed
36.
Dimopoulos MA, Moreau P, Palumbo A et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17:27–38PubMed
37.
Dobbin SJH, Cameron AC, Petrie MC et al (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart 104:1995–2002PubMed
38.
Doherty KR, Wappel RL, Talbert DR et al (2013) Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 272:245–255PubMed
39.
Escudier M, Cautela J, Malissen N et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085–2087PubMed
40.
Fahdi IE, Gaddam V, Saucedo JF et al (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93:1052–1055PubMed
41.
Fiuza M, Ribeiro L, Magalhaes A et al (2016) Organization and implementation of a cardio-oncology program. Rev Port Cardiol 35:485–494PubMed
42.
Fradley MG, Groarke JD, Laubach J et al (2018) Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol 180:271–275PubMed
43.
Ganatra S, Sharma A, Shah S et al (2018) Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol 4:1491–1500PubMed
44.
Gandini S, Puntoni M, Heckman-Stoddard BM et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7:867–885
45.
Ghatalia P, Je Y, Kaymakcalan MD et al (2015) QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112:296–305PubMed
46.
Ghatalia P, Morgan CJ, Je Y et al (2015) Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 94:228–237PubMed
47.
Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674–1685PubMedPubMedCentral
48.
Goel S, Liu J, Guo H et al (2019) Decline in left ventricular ejection fraction following anthracyclines predicts trastuzumab cardiotoxicity. JACC Heart Fail 7:795–804PubMed
49.
Groarke JD, Nguyen PL, Nohria A et al (2014) Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J 35:612–623PubMed
50.
Guglin M, Krischer J, Tamura R et al (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73:2859–2868PubMedPubMedCentral
51.
Guignabert C, Phan C, Seferian A et al (2016) Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 126:3207–3218PubMedPubMedCentral
52.
Haas NB, Manola J, Ky B et al (2015) Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805. Clin Cancer Res 21:4048–4054PubMedPubMedCentral
53.
Haddy N, Diallo S, El-Fayech C et al (2016) Cardiac diseases following childhood cancer treatment. Circulation 133:31–38PubMed
54.
Hamadi A, Grigg AP, Dobie G et al (2019) Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response. Thromb Haemost 119:1112–1123PubMed
55.
Heckmann MB, Doroudgar S, Katus HA et al (2018) Cardiovascular adverse events in multiple myeloma patients. J Thorac Dis 10:S4296–S4305PubMedPubMedCentral
56.
Hequet O, Le QH, Moullet I et al (2004) Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864–1871PubMed
57.
Hilfiker-Kleiner D, Ardehali H, Fischmeister R et al (2019) Late onset heart failure after childhood chemotherapy. Eur Heart J 40:798–800PubMedPubMedCentral
58.
Hooning MJ, Botma A, Aleman BMP et al (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99:365–375PubMed
59.
Hu JR, Florido R, Lipson EJ et al (2019) Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115:854–868PubMedPubMedCentral
60.
Jaworski C, Mariani JA, Wheeler G et al (2013) Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61:2319–2328PubMed
61.
Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177:237–250PubMedPubMedCentral
62.
Jiang L, Li L, Ruan Y et al (2019) Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm 16:1374–1382PubMed
63.
John S, Antonia SJ, Rose TA et al (2017) Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab—durvalumab treatment. J Immunother Cancer 5:54PubMedPubMedCentral
64.
Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755PubMedPubMedCentral
65.
Kloth JS, Pagani A, Verboom MC et al (2015) Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer 112:1011–1016PubMedPubMedCentral
66.
Knight R, Delap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079–2080PubMed
67.
Kosalka P, Johnson C, Turek M et al (2019) Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer. Curr Oncol 26:e314–e321PubMedPubMedCentral
68.
Lancellotti P, Nkomo VT, Badano LP et al (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 14:721–740PubMed
69.
Lancellotti P, Suter TM, Lopez-Fernandez T et al (2019) Cardio-oncology services: rationale, organization, and implementation. Eur Heart J 40:1756–1763PubMed
70.
Langer T, Grabow D, Kaatsch P et al (2018of) Long-Term Follow-Up in Childhood Cancer Survivors—Position paper 2018 of the working group “long-term follow-up” of the Society of Pediatric Oncology and Hematology (GPOH) on long-term surveillance, long-term follow-up and late effect evaluation in pediatric oncology patients. Klin Padiatr 230:291–298PubMed
71.
Larson RA, Kim D‑W, Issaragrilsil S et al (2014) Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f/u) of ENESTnd. Blood 124:4541–4541
72.
Latifi Y, Moccetti F, Wu M et al (2019) Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood 133:1597–1606PubMedPubMedCentral
73.
Chuy LK, Nahhas O, Dominic P et al (2019) Cardiovascular complications associated with mediastinal radiation. Curr Treat Options Cardiovasc Med 21:31
74.
Lee DH, Fradley MG (2018) Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention. Curr Treat Options Cardiovasc Med 20:19PubMed
75.
Lee HA, Hyun SA, Byun B et al (2018) Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes. PLoS ONE 13:e195577PubMedPubMedCentral
76.
Lehmann LH, Worst BC, Stanmore DA et al (2014) Histone deacetylase signaling in cardioprotection. Cell Mol Life Sci 71:1673–1690PubMed
77.
Lenihan DJ, Cardinale DM (2012) Late cardiac effects of cancer treatment. J Clin Oncol 30:3657–3664PubMed
78.
Lenihan DJ, Hartlage G, Decara J et al (2016) Cardio-oncology training: a proposal from the international cardioncology society and Canadian Cardiac Oncology network for a new multidisciplinary specialty. J Card Fail 22:465–471PubMed
79.
Leonard JT, Rowley JS, Eide CA et al (2016) Targeting BCL‑2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med 8:354ra114PubMed
80.
Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272PubMed
81.
Lipshultz SE, Adams MJ, Colan SD et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128:1927–1995PubMed
82.
Lustberg MB, Reinbolt R, Addison D et al (2019) Early detection of anthracycline-induced cardiotoxicity in breast cancer survivors with T2 cardiac magnetic resonance. Circ Cardiovasc Imaging 12:e8777PubMedPubMedCentral
83.
Lynce F, Barac A, Geng X et al (2019) Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 175:595–603PubMedPubMedCentral
84.
Lyon AR, Yousaf N, Battisti NML et al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19:e447–e458PubMed
85.
Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755–1764PubMedPubMedCentral
86.
Mccabe MS, Bhatia S, Oeffinger KC et al (2013) American society of clinical oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 31:631–640PubMedPubMedCentral
87.
Mclaughlin PY, Kong W, De Metz C et al (2018) Do radiation oncology outreach clinics affect the use of radiotherapy? Radiother Oncol 127:143–149PubMed
88.
Medeiros BC, Possick J, Fradley M (2018) Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Rev 32:289–299PubMed
89.
Meid AD, Bighelli I, Machler S et al (2017) Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol 7:251–264PubMedPubMedCentral
90.
Meijers WC, De Boer RA (2019) Common risk factors for heart failure and cancer. Cardiovasc Res 115:844–853PubMedPubMedCentral
91.
92.
Michel L, Rassaf T, Totzeck M (2018) Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 10:S4282–S4295PubMedPubMedCentral
93.
Mincu RI, Mahabadi AA, Michel L et al (2019) Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. Jama Netw Open 2:e198890PubMedPubMedCentral
94.
Moller TR, Garwicz S, Barlow L et al (2001) Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 19:3173–3181PubMed
95.
Moreau P, San Miguel J, Sonneveld P et al (2017) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52–iv61PubMed
96.
Moslehi JJ, Johnson DB, Sosman JA (2017) Myocarditis with immune checkpoint blockade. N Engl J Med 376:292PubMed
97.
Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933PubMedPubMedCentral
98.
Mulrooney DA, Yeazel MW, Kawashima T et al (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606PubMedPubMedCentral
99.
Murphy KT (2016) The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am J Physiol Heart Circ Physiol 310:H466–H477PubMed
100.
Narayan V, Keefe S, Haas N et al (2017) Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res 23:3601–3609PubMedPubMedCentral
101.
Nelson ER, Wardell SE, Jasper JS et al (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094–1098PubMedPubMedCentral
102.
Nhola LF, Abdelmoneim SS, Villarraga HR et al (2019) Echocardiographic assessment for the detection of cardiotoxicity Due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers. J Am Soc Echocardiogr 32:267–276PubMed
103.
Nowis D, Maczewski M, Mackiewicz U et al (2010) Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 176:2658–2668PubMedPubMedCentral
104.
Nowsheen S, Aziz K, Park JY et al (2018) Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction. J Am Heart Assoc 7:e8637PubMedPubMedCentral
105.
Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582PubMed
106.
Okwuosa TM, Akhter N, Williams KA et al (2015) Building a cardio-oncology program in a small- to medium-sized, nonprimary cancer center, academic hospital in the USA: challenges and pitfalls. Future Cardiol 11:413–420PubMed
107.
Ou SH, Tang Y, Polli A et al (2016) Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med 5:617–622PubMedPubMedCentral
108.
Parent S, Pituskin E, Paterson DI (2016) The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol 32:847–851PubMed
109.
110.
Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911–939PubMed
111.
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200PubMed
112.
Qazilbash MH, Amjad AI, Qureshi S et al (2009) Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 15:1265–1270PubMedPubMedCentral
113.
Ranchoux B, Gunther S, Quarck R et al (2015) Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 185:356–371PubMed
114.
Rea D, Mirault T, Raffoux E et al (2015) Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia 29:1206–1209PubMed
115.
Reneau JC, Asante D, Van Houten H et al (2017) Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: a propensity matched study of 1,790 patients. Am J Hematol 92:E15–E17PubMed
116.
117.
Rodriguez-Veiga R, Igual B, Montesinos P et al (2017) Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. Ann Hematol 96:1077–1084PubMed
118.
Rosenthal A, Luthi J, Belohlavek M et al (2016) Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J 6:e384PubMedPubMedCentral
119.
Salem JE, Allenbach Y, Vozy A et al (2019) Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 380:2377–2379PubMed
120.
Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579–1589PubMedPubMedCentral
121.
Sara JD, Kaur J, Khodadadi R et al (2018) 5‑fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 10:1758835918780140PubMedPubMedCentral
122.
Scherr M, Kirchhoff H, Battmer K et al (2019) Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia 33:1313–1323PubMed
123.
Shah MH, Binkley P, Chan K et al (2006) Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12:3997–4003PubMed
124.
Shah NP, Wallis N, Farber HW et al (2015) Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90:1060–1064PubMed
125.
Siegel D, Martin T, Nooka A et al (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98:1753–1761PubMedPubMedCentral
126.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMed
127.
Sorror ML, Giralt S, Sandmaier BM et al (2007) Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 110:4606–4613PubMedPubMedCentral
128.
Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919PubMedPubMedCentral
129.
Steingart RM, Bakris GL, Chen HX et al (2012) Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 163:156–163PubMed
130.
Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677PubMed
131.
Stewart AK (2015) Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Future Oncol 11:2121–2136PubMed
132.
Stocks T, Van Hemelrijck M, Manjer J et al (2012) Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension 59:802–810PubMed
133.
Stuhlmiller TJ, Zawistowski JS, Chen X et al (2017) Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and Sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. J Am Heart Assoc. https://​doi.​org/​10.​1161/​JAHA.​117.​006635 CrossRefPubMedPubMedCentral
134.
Subramanian S, Bates SE, Wright JJ et al (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3:2751–2767PubMedPubMedCentral
135.
Sun H, Li T, Zhuang R et al (2017) Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies. Medicine 96:e6394PubMedPubMedCentral
136.
Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127–1134PubMed
137.
Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879PubMed
138.
Taylor C, Correa C, Duane FK et al (2017) Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35:1641–1649PubMedPubMedCentral
139.
Terpos E, Kleber M, Engelhardt M et al (2015) European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254–1266PubMedPubMedCentral
140.
Tilemann LM, Heckmann MB, Katus HA et al (2018) Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol 107:271–280PubMedPubMedCentral
141.
Totzeck M, Schuler M, Stuschke M et al (2019) Cardio-oncology—strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163–175PubMed
142.
Trachtenberg BH, Landy DC, Franco VI et al (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342–353PubMed
143.
Van Der PHJ, Van Dalen EC, Hauptmann M et al (2010) Cardiac function in 5‑year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 170:1247–1255
144.
Van Nimwegen FA, Schaapveld M, Janus CP et al (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175:1007–1017PubMed
145.
Weatherald J, Chaumais MC, Savale L et al (2017) Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 50(1):1700217PubMed
146.
Weberpals J, Jansen L, Muller OJ et al (2018) Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J 39:3896–3903PubMed
147.
Wiczer TE, Levine LB, Brumbaugh J et al (2017) Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 1:1739–1748PubMedPubMedCentral
148.
Yoon HJ, Kim KH, Kim HY et al (2019) Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol 108:892–900PubMed
149.
Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801PubMed
150.
Metadaten
Titel
Onkologische Kardiologie
Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie
verfasst von
Univ.-Prof. Dr. med. Tienush Rassaf
Matthias Totzeck
Johannes Backs
Carsten Bokemeyer
Michael Hallek
Denise Hilfiker-Kleiner
Andreas Hochhaus
Diana Lüftner
Oliver J. Müller
Ulrich Neudorf
Roman Pfister
Stephan von Haehling
Lorenz H. Lehmann
Johann Bauersachs
die Kommission für Klinische Kardiovaskuläre Medizin der DGK
Publikationsdatum
13.05.2020
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 4/2020
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-020-00395-z

Weitere Artikel der Ausgabe 4/2020

Die Kardiologie 4/2020 Zur Ausgabe

Praxiswissen EKG-Interpretation

Lungenherde, Bewusstseinsstörungen und Dyspnoe – was sehen Sie im EKG?

Leitlinien

Neue ESC.Leitlinie zur akuten Lungenembolie – für Sie kommentiert

Originalien

„Ein vornehmer und nobler Charakter“: Die Nobelpreisnominierungen für Hugo W. Knipping

Journal Club

Thrombus im linken Ventrikel: Diagnostik mit Herz-MRT und Echokardiographie sowie Embolierisiko

CME

Tako-Tsubo-Syndrom

Leitlinien

Kommentar zu den Leitlinien (2019) der ESC/EAS zur Diagnostik und Therapie der Dyslipidämien

Passend zum Thema

ANZEIGE

Umfrage: Topika mit Dexpanthenol bei Radiodermatitis empfohlen

In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1]. 

ANZEIGE

Handekzem: Adhärenz bei topischer Therapie nicht zufriedenstellend

Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1]. 

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bayer Vital GmbH

Weitere Lesetipps

ANZEIGE

Im Dialog mit jungen Dermatologen: Wund- und Narbenversorgung in der Praxis

Was eine strahlend schöne Haut ausmacht

ANZEIGE

Dexpanthenol verstärkt die positiven Effekte der LASH-Methode

Aktuelle Erkenntnisse zum Sensitive-Skin-Syndrom

Neoadjuvante Bestrahlung bei Rektum-Ca. oft überflüssig

ANZEIGE

Spektrum Dermatologie: Jetzt auch auf medbee – die App für Mediziner*innen

Bildnachweise